Auris Medical recently reported its Q318 results and provided a brief business update on its active programs. R&D expenditure for the period was down roughly 60% over Q317, which reflects management’s swift pivot to focus on Phase I development. Auris plans to initiate two intranasal betahistine trials in Q119: the AM-125 Phase II trial in acute vertigo and AM-201 Phase I trial for olanzapine-induced weight gain.
19 Nov 2018
Auris Medical Holding - Q318 results and business updates
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Auris Medical Holding - Q318 results and business updates
Altamira Therapeutics Ltd. (CYTO:NAS) | 0 0 0.0%
- Published:
19 Nov 2018 -
Author:
Maxim Jacobs -
Pages:
6
Auris Medical recently reported its Q318 results and provided a brief business update on its active programs. R&D expenditure for the period was down roughly 60% over Q317, which reflects management’s swift pivot to focus on Phase I development. Auris plans to initiate two intranasal betahistine trials in Q119: the AM-125 Phase II trial in acute vertigo and AM-201 Phase I trial for olanzapine-induced weight gain.